Eli Lilly and (LLY)

Key Points in This Article: Dividend growth investing offers stable income and capital appreciation through compounding returns.

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill orforglipron disappointed.

I initiate my coverage on Eli Lilly with a 'Buy' after an eventful Q2 earnings season. The stock looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbou...

After crushing the market over the past few years, Eli Lilly (LLY 2.73%) is finally feeling the effects of gravity. The company has faced a pair of setbacks this year.

We're well into the home stretch of 2025. August is more than halfway over.

Eli Lilly's recent 20% pullback is a buy-the-dip opportunity, as the market overreacted to mixed Orforglipron results. Blockbuster drugs Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 9...

Former hedge fund manager and CNBC's Mad Money host Jim Cramer has dismissed fears that the stock market might be heading for another Dot-com style meltdown.

Wall Street loves a dominant player, and Eli Lilly (LLY 2.73%) looks unstoppable with its obesity blockbusters printing money faster than the Fed. But here's what the bulls aren't telling you: The com...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

On Thursday, Eli Lilly and Co. LLY said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.